Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Coherus Oncology, Inc.CHRS · Entity 6276 | Director | February 01, 2018 | February 05, 2018 |
| Medpace Holdings, Inc.MEDP · Entity 3327 | Director · President & CEO · 10% owner | September 29, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Coherus Oncology, Inc.
Report date February 01, 2018 · Filed February 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.05 · Expires 2028-02-01 | Direct | 20,000 |
Reported balance
After 2018-02-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-02-01 · Grant · Acquired 20,000 · Balance 20,000 F3: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. |
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 29,994 |
Reported balance
Holding disclosure · report date 2018-02-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 29,994 |
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | IndirectSee Footnote | 1,642,492 |
Reported balance
Holding disclosure · report date 2018-02-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,642,492 F1: The shares are held by MX II Associates LLC ("MX II Associates"). Reporting Person is the Managing Member of MX II Associates. Voting and dispositive decisions with respect to shares held by MX II Associates are made by Reporting Person, however, Reporting Person disclaims beneficial ownership of the shares held by MX II Associates, except to the extent of any pecuniary interest therein. |
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | IndirectSee Footnote | 268,428 |
Reported balance
Holding disclosure · report date 2018-02-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 268,428 F2: The shares are held by Medpace Investors, LLC ("Medpace Investors"). Reporting Person is the Manager of Medpace Investors. Voting and dispositive decisions with respect to shares held by Medpace Investors are made by Reporting Person, however, Reporting Person disclaims beneficial ownership of the shares held by Medpace Investors, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held by MX II Associates LLC ("MX II Associates"). Reporting Person is the Managing Member of MX II Associates. Voting and dispositive decisions with respect to shares held by MX II Associates are made by Reporting Person, however, Reporting Person disclaims beneficial ownership of the shares held by MX II Associates, except to the extent of any pecuniary interest therein.
F2: The shares are held by Medpace Investors, LLC ("Medpace Investors"). Reporting Person is the Manager of Medpace Investors. Voting and dispositive decisions with respect to shares held by Medpace Investors are made by Reporting Person, however, Reporting Person disclaims beneficial ownership of the shares held by Medpace Investors, except to the extent of any pecuniary interest therein.
F3: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
Medpace Holdings, Inc.
Report date September 29, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 338,225 |
Ending reported balance
After 2026-09-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-29 · Sale · Disposed 26,701 · Balance 360,191 F1: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $622.35. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Row 2 · 2026-09-30 · Sale · Disposed 21,966 · Balance 338,225 F1: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F3: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.105 to $628.08. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. |
| Common StockSEC Table I · non-derivative | IndirectBy Medpace Investors, LLC | 4,733,019 |
Reported balance
Holding disclosure · report date 2026-09-29 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 4,733,019 F4: The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.
F2: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $622.35. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
F3: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.105 to $628.08. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
F4: The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 07, 2025 Filed Mar 10, 2025 21:47 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | Exercise / conversionCommon Stock | 37,417 | $54.74 | $2,048,206.58 |
DisclosureSEC source: 0001668397-25-000033 · wk-form4_1741643264.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 692,073 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 21:47 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | GrantEmployee Stock Option (Right to Buy) · Derivative | 73,443 | $0.00 Strike: $325.73 | $0.00 |
DisclosureSEC source: 0001668397-25-000033 · wk-form4_1741643264.xml · derivative · entry 5 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,443 Underlying: Common Stock · 73,443 shares Expires 2034-03-06 F2 · derivative.exercise_date: The option vests immediately upon issuance. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 20:14 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | GrantEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $377.00 | $0.00 |
DisclosureSEC source: 0001668397-24-000145 · wk-form4_1723061647.xml · derivative · entry 3 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-08-05 F2 · derivative.exercise_date: The option vests immediately upon issuance. Read SEC document |
| May 28, 2024 Filed May 29, 2024 20:24 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 5,695 | $395.49 | $2,252,315.55 |
DisclosureSEC source: 0001668397-24-000121 · wk-form4_1717014244.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 654,656 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $395.00 to $396.33. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| May 24, 2024 Filed May 29, 2024 20:24 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 3,987 | $395.22 | $1,575,742.14 |
DisclosureSEC source: 0001668397-24-000121 · wk-form4_1717014244.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 660,351 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $395.00 to $396.13. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| May 22, 2024 Filed May 24, 2024 20:10 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 55 | $400.00 | $22,000.00 |
DisclosureSEC source: 0001668397-24-000119 · wk-form4_1716581437.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 664,338 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a limit order placed by the Reporting Person during an open window period. Read SEC document |
| May 20, 2024 Filed May 22, 2024 20:20 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 4,020 | $400.19 | $1,608,763.80 |
DisclosureSEC source: 0001668397-24-000117 · wk-form4_1716409244.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 664,393 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $400.00 to $400.50. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| May 16, 2024 Filed May 17, 2024 20:12 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 7,060 | $403.09 | $2,845,815.40 |
DisclosureSEC source: 0001668397-24-000103 · wk-form4_1715976696.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 668,413 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $400.00 to $407.565. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:12 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 32,282 | $405.13 | $13,078,406.66 |
DisclosureSEC source: 0001668397-24-000103 · wk-form4_1715976696.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 675,473 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $400.00 to $407.70. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| May 10, 2024 Filed May 14, 2024 20:11 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 4,956 | $402.89 | $1,996,722.84 |
DisclosureSEC source: 0001668397-24-000101 · wk-form4_1715717497.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 707,755 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $400.00 to $406.49. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| May 09, 2024 Filed May 10, 2024 20:24 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 3,486 | $400.17 | $1,394,992.62 |
DisclosureSEC source: 0001668397-24-000099 · wk-form4_1715372663.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 712,711 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $400.00 to $400.67. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| May 08, 2024 Filed May 10, 2024 20:24 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 4,782 | $400.58 | $1,915,573.56 |
DisclosureSEC source: 0001668397-24-000099 · wk-form4_1715372663.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 716,197 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $400.00 to $402.475. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| May 07, 2024 Filed May 8, 2024 20:08 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 28,032 | $404.48 | $11,338,383.36 |
DisclosureSEC source: 0001668397-24-000097 · wk-form4_1715198868.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 720,979 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $400.00 to $408.62. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| May 06, 2024 Filed May 8, 2024 20:08 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 24,372 | $401.73 | $9,790,963.56 |
DisclosureSEC source: 0001668397-24-000097 · wk-form4_1715198868.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 749,011 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $400.00 to $404.94. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| May 02, 2024 Filed May 3, 2024 20:07 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 3,396 | $400.44 | $1,359,894.24 |
DisclosureSEC source: 0001668397-24-000095 · wk-form4_1714766812.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 773,383 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $400.00 to $401.60. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:07 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 12,934 | $401.56 | $5,193,777.04 |
DisclosureSEC source: 0001668397-24-000095 · wk-form4_1714766812.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 776,779 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $400.00 to $403.47. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| April 30, 2024 Filed May 1, 2024 20:22 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 1,828 | $400.31 | $731,766.68 |
DisclosureSEC source: 0001668397-24-000093 · wk-form4_1714594944.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 789,713 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $400.00 to $400.92. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| April 29, 2024 Filed May 1, 2024 20:22 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 15,102 | $400.69 | $6,051,220.38 |
DisclosureSEC source: 0001668397-24-000093 · wk-form4_1714594944.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 791,541 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $400.00 to $402.82. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| March 08, 2024 Filed Mar 8, 2024 22:08 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 25,000 | $408.71 | $10,217,750.00 |
DisclosureSEC source: 0001668397-24-000057 · wk-form4_1709935676.xml · nonDerivative · entry 3 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 4,733,019 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $402.90 to $414.195. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 22:08 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 75,000 | $410.74 | $30,805,500.00 |
DisclosureSEC source: 0001668397-24-000057 · wk-form4_1709935676.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 4,758,019 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $406.33 to $415.64. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 22:08 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 100,000 | $412.98 | $41,298,000.00 |
DisclosureSEC source: 0001668397-24-000057 · wk-form4_1709935676.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 4,833,019 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $406.36 to $419.42. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 05, 2024 Filed Mar 6, 2024 21:36 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 50,000 | $402.70 | $20,135,000.00 |
DisclosureSEC source: 0001668397-24-000049 · wk-form4_1709760994.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 4,933,019 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $400.00 to $404.39. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 21:36 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 50,000 | $403.12 | $20,156,000.00 |
DisclosureSEC source: 0001668397-24-000049 · wk-form4_1709760994.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 4,983,019 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $400.52 to $408.21. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 21:15 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 80,000 | $401.88 | $32,150,400.00 |
DisclosureSEC source: 0001668397-24-000043 · wk-form4_1709586674.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,033,019 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $400.00 to $404.88. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 21:15 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 20,000 | $393.71 | $7,874,200.00 |
DisclosureSEC source: 0001668397-24-000043 · wk-form4_1709586674.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,113,019 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $390.41 to $401.90. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 21:16 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 50,000 | $404.13 | $20,206,500.00 |
DisclosureSEC source: 0001668397-24-000035 · wk-form4_1709241398.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,133,019 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $400.105 to $407.27. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:16 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 50,000 | $401.88 | $20,094,000.00 |
DisclosureSEC source: 0001668397-24-000035 · wk-form4_1709241398.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,183,019 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $398.84 to $404.17. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 21:17 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 56,928 | $402.38 | $22,906,688.64 |
DisclosureSEC source: 0001668397-24-000027 · wk-form4_1709068610.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,233,019 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $397.98 to $405.72. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:17 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 100,000 | $400.32 | $40,032,000.00 |
DisclosureSEC source: 0001668397-24-000027 · wk-form4_1709068610.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,289,947 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $396.15 to $402.50. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 21:11 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 100,000 | $395.98 | $39,598,000.00 |
DisclosureSEC source: 0001668397-24-000021 · wk-form4_1708722670.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,389,947 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $390.86 to $401.45. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 21:11 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 36,012 | $383.44 | $13,808,441.28 |
DisclosureSEC source: 0001668397-24-000021 · wk-form4_1708722670.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,489,947 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $379.96 to $386.56. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 21:45 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 13,988 | $386.39 | $5,404,823.32 |
DisclosureSEC source: 0001668397-24-000015 · wk-form4_1708551923.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,525,959 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $385.00 to $389.34. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:45 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 50,000 | $391.75 | $19,587,500.00 |
DisclosureSEC source: 0001668397-24-000015 · wk-form4_1708551923.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,539,947 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $390.06 to $394.95. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 01, 2023 Filed Dec 1, 2023 21:26 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 24,039 | $273.26 | $6,568,897.14 |
DisclosureSEC source: 0000892251-23-000195 · form4.xml · nonDerivative · entry 4 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,589,947 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period. F6 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $272.00 to $274.565. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 30, 2023 Filed Dec 1, 2023 21:26 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 7,871 | $272.18 | $2,142,328.78 |
DisclosureSEC source: 0000892251-23-000195 · form4.xml · nonDerivative · entry 3 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,613,986 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $272.00 to $273.75. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 29, 2023 Filed Dec 1, 2023 21:26 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 18,090 | $272.62 | $4,931,695.80 |
DisclosureSEC source: 0000892251-23-000195 · form4.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,621,857 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $272.00 to $274.415. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 29, 2023 Filed Dec 1, 2023 21:26 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 3,167 | $272.87 | $864,179.29 |
DisclosureSEC source: 0000892251-23-000195 · form4.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,639,947 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $272.06 to $273.955. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 28, 2023 Filed Nov 29, 2023 21:16 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 21,833 | $273.66 | $5,974,818.78 |
DisclosureSEC source: 0000892251-23-000192 · form4.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,643,114 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $272.00 to $275.91. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 27, 2023 Filed Nov 29, 2023 21:16 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 25,000 | $276.10 | $6,902,500.00 |
DisclosureSEC source: 0000892251-23-000192 · form4.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,664,947 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $274.26 to $279.50. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 22, 2023 Filed Nov 27, 2023 21:42 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 25,000 | $277.81 | $6,945,250.00 |
DisclosureSEC source: 0000892251-23-000191 · form4.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,689,947 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $275.59 to $279.52. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 21, 2023 Filed Nov 22, 2023 21:15 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 25,000 | $277.37 | $6,934,250.00 |
DisclosureSEC source: 0000892251-23-000186 · form4.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,714,947 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $275.67 to $279.49. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 20, 2023 Filed Nov 21, 2023 21:16 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 50,000 | $275.45 | $13,772,500.00 |
DisclosureSEC source: 0000892251-23-000184 · form4.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,739,947 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $272.00 to $277.805. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 21:16 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 50,000 | $273.91 | $13,695,500.00 |
DisclosureSEC source: 0000892251-23-000184 · form4.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,789,947 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $272.00 to $279.85. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 16, 2023 Filed Nov 16, 2023 21:43 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 17,000 | $281.61 | $4,787,370.00 |
DisclosureSEC source: 0000892251-23-000183 · form4.xml · nonDerivative · entry 3 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,839,947 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $280.10 to $284.11. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 15, 2023 Filed Nov 16, 2023 21:43 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 33,000 | $283.42 | $9,352,860.00 |
DisclosureSEC source: 0000892251-23-000183 · form4.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,856,947 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $282.00 to $286.53. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:43 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 25,000 | $283.11 | $7,077,750.00 |
DisclosureSEC source: 0000892251-23-000183 · form4.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,889,947 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $281.20 to $286.67. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 21, 2023 Filed Sep 22, 2023 01:41 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 61,655 | $244.27 | $15,060,466.85 |
DisclosureSEC source: 0000950170-23-049303 · ownership.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,914,947 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on May 1 2023. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $239.77 to $251.58. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 20, 2023 Filed Sep 22, 2023 01:41 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 65,653 | $255.48 | $16,773,028.44 |
DisclosureSEC source: 0000950170-23-049303 · ownership.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,976,602 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on May 1 2023. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $253.07 to $257.935. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 20:15 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 137,379 | $259.66 | $35,671,831.14 |
DisclosureSEC source: 0000892251-23-000144 · form4.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,042,255 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on May 1, 2023. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $254.74 to $271.42. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 18, 2023 Filed Sep 20, 2023 20:15 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 53,385 | $274.76 | $14,668,062.60 |
DisclosureSEC source: 0000892251-23-000144 · form4.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,179,634 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on May 1, 2023. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $271.505 to $278.665. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.